Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. (SHE:301290)
China · Delayed Price · Currency is CNY 25.70
-0.47 (-1.80%)
At close: Nov 13, 2026
SHE:301290 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,536 | 2,494 | 2,293 | 2,764 | 3,749 | - | |
Market Cap Growth | -3.85% | 8.73% | -17.02% | -26.29% | - | - |
Enterprise Value | 1,965 | 1,365 | 1,151 | 1,581 | 3,568 | - |
Last Close Price | 25.70 | 25.02 | 22.45 | 25.88 | 34.61 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 34.02 | - | 23.54 | 28.43 | 36.58 | - |
PS Ratio | 5.85 | 6.44 | 5.27 | 6.37 | 8.48 | - |
PB Ratio | 1.18 | 1.16 | 1.02 | 1.23 | 1.70 | - |
P/TBV Ratio | 2.25 | 1.51 | 1.41 | 1.74 | 2.45 | - |
P/FCF Ratio | 69.69 | 65.58 | 217.68 | 53.48 | 184.90 | - |
P/OCF Ratio | 26.71 | 29.66 | 18.13 | 16.94 | 39.62 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.53 | 3.52 | 2.64 | 3.64 | 8.07 | - |
EV/EBITDA Ratio | 19.69 | 14.92 | 9.95 | 14.43 | 25.27 | - |
EV/EBIT Ratio | 33.67 | 27.09 | 15.64 | 21.97 | 33.36 | - |
EV/FCF Ratio | 54.00 | 35.90 | 109.29 | 30.59 | 175.95 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.20 | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 4.35 | 1.28 | 0.31 | 0.02 | 0.02 | 0.01 |
Debt / FCF Ratio | 11.92 | 3.10 | 3.37 | 0.04 | 0.11 | 0.02 |
Net Debt / Equity Ratio | -0.28 | -0.54 | -0.52 | -0.55 | -0.56 | -0.18 |
Net Debt / EBITDA Ratio | -6.19 | -12.65 | -10.07 | -11.32 | -8.71 | -1.28 |
Net Debt / FCF Ratio | -16.79 | -30.45 | -110.64 | -24.01 | -60.62 | -2.84 |
Asset Turnover | 0.16 | 0.16 | 0.18 | 0.18 | 0.24 | 0.38 |
Inventory Turnover | 0.92 | 1.79 | 2.06 | 2.23 | 2.19 | 2.18 |
Quick Ratio | 2.32 | 5.27 | 6.21 | 10.56 | 8.49 | 2.33 |
Current Ratio | 3.03 | 5.74 | 6.79 | 11.43 | 9.21 | 3.11 |
Return on Equity (ROE) | 3.36% | -1.81% | 4.31% | 4.49% | 6.28% | 10.66% |
Return on Assets (ROA) | 1.34% | 1.28% | 1.89% | 1.88% | 3.68% | 6.45% |
Return on Invested Capital (ROIC) | 3.80% | 4.83% | 5.92% | 6.20% | 9.85% | 12.22% |
Return on Capital Employed (ROCE) | 2.30% | 2.30% | 3.20% | 3.20% | 4.80% | 11.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.94% | -1.52% | 4.25% | 3.52% | 2.73% | - |
FCF Yield | 1.43% | 1.52% | 0.46% | 1.87% | 0.54% | - |
Dividend Yield | 1.17% | 1.19% | 2.58% | 2.17% | 1.34% | - |
Payout Ratio | 43.29% | - | 61.17% | 51.52% | - | - |
Buyback Yield / Dilution | 1.60% | -0.43% | 0.81% | -30.05% | -2.76% | -10.45% |
Total Shareholder Return | 2.77% | 0.76% | 3.40% | -27.87% | -1.43% | -10.45% |